ACS
SGMO

Archford Capital Strategies’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Archford Capital Strategies’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4,500
Closed -$20K – 734
2016
Q3 		$20K Hold
4,500
– – 0.01% 328
2016
Q2 		$26K Buy
+4,500
New +$28.7K 0.01% 312
2016
Q1 		– Sell
-4,500
Closed -$42K – 521
2015
Q4 		$42K Hold
4,500
– – 0.02% 276
2015
Q3 		$25K Hold
4,500
– – 0.02% 253
2015
Q2 		$50K Hold
4,500
– – 0.04% 195
2015
Q1 		$70.6K Hold
4,500
– – 0.05% 178
2014
Q4 		$68K Hold
4,500
– – 0.05% 179
2014
Q3 		$49K Hold
4,500
– – 0.04% 208
2014
Q2 		$68.7K Hold
4,500
– – 0.05% 186
2014
Q1 		$81.4K Buy
+4,500
New +$86.7K 0.07% 170

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FC
FIC Capital New York $262M AUM 34.37% 1-Year Est. Return

Archford Capital Strategies's SGMO Position: Q4 2016 in Review

Archford Capital Strategies sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2016, closing a stake of 4,500 shares — an estimated $20K sold.

Archford Capital Strategies first reported a position in SGMO in Q1 2014 and held it in 10 quarters. The position peaked at $81.4K in Q1 2014. 126 funds tracked by Wall St. Rank hold SGMO as of Q4 2016.

  • Archford Capital Strategies reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2016 after selling out during the quarter.
  • Archford Capital Strategies sold 4,500 SANGAMO THERAPEUTICS INC shares in Q4 2016, an estimated $20K.
  • Archford Capital Strategies first reported a position in SANGAMO THERAPEUTICS INC in Q1 2014 and held it in 10 quarters.
  • Archford Capital Strategies's SANGAMO THERAPEUTICS INC position peaked at $81.4K in Q1 2014.
  • 126 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2016.

Based on Archford Capital Strategies's 13F filing for Q4 2016, filed 15 Feb 2017.